Tiffany Beck, MD
Gynecologic Oncology · Newport Beach, CANPI 1619144151
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,000 of the $4,963 with a category attached, or 80.6%. Intuitive Surgical accounts for 84.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $4,226 and has fallen 99.6% since, to $15 in 2025.
Across 18 payments — averaging $275.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$287
- Medtronic$172
- Immunogen, Inc.$136
- Merck$83
- Genentech USA, Inc.$28
- plus $85 from 4 others
Across 5 payments — averaging $8951.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$26K
- AbbVie$18K
What the payments were for
- Food & beverage$96319%
- Education$4,00081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $4,170 |
| GSK | 5 | $287 |
| Medtronic | 2 | $172 |
| Immunogen, Inc. | 1 | $136 |
| Merck | 1 | $83 |
| Genentech USA, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $25 |
| Mylan Institutional Inc. | 1 | $23 |
| Clovis Oncology, Inc. | 1 | $23 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,150
- Abre$157
- Elahere$136
- JEMPERLI$121
- ZEJULA$118
How this compares
$4,963 in reported general payments places this provider in the 65th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 15 | $156 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Newport Beach
- Alberto MendivilNewport Beach$68K
- Lisa AbaidNewport Beach$13K
- John BrownNewport Beach$6K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.